Covestor’s Nektar Therapeutics NKTR Stock Holding History

Covestor’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Hold	0	–	–	–	2563
2025 Q1	–	Hold	0	–	–	–	2557
2024 Q4	–	Hold	0	–	–	–	2564
2024 Q3	–	Hold	0	–	–	–	2560
2024 Q2	–	Sell	-2	Closed	-$42	–	2574
2024 Q1	$0	Sell	2 -3	-60%	-$31	﹤0.01%	2570
2023 Q4	$0	Hold	5	–	–	﹤0.01%	2511
2023 Q3	$0	Sell	5 -1	-17%	-$10	﹤0.01%	2498
2023 Q2	$0	Buy	6 +4	+200%	+$43	﹤0.01%	2469
2023 Q1	$0	Hold	2	–	–	﹤0.01%	2392
2022 Q4	$0	Hold	2	–	–	﹤0.01%	2413
2022 Q3	$0	Sell	2 -1	-33%	-$59	﹤0.01%	2383
2022 Q2	$0	Buy	3 +1	+50%	+$63	﹤0.01%	2200
2022 Q1	$0	Sell	2 -1	-33%	-$148	﹤0.01%	2316
2021 Q4	$1K	Buy	+3	New	+$651	﹤0.01%	1855

Other funds holding NKTR

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Covestor's NKTR Position: Q2 2025 in Review

Covestor held its Nektar Therapeutics (NKTR) position steady in Q2 2025 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #2563.

Covestor first reported a position in NKTR in Q4 2021 and has held it in 10 quarters since. The position peaked at $1K in Q4 2021. 109 funds tracked by Wall St. Rank hold NKTR as of Q2 2025.

Covestor held 0 shares of Nektar Therapeutics worth $0 as of Q2 2025.
Covestor left its Nektar Therapeutics share count unchanged in Q2 2025.
Nektar Therapeutics made up ﹤0.01% of Covestor's portfolio in Q2 2025, its #2563 holding.
Covestor first reported a position in Nektar Therapeutics in Q4 2021 and has held it in 10 quarters since.
Covestor's Nektar Therapeutics position peaked at $1K in Q4 2021.
109 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2025.

Based on Covestor's 13F filing for Q2 2025, filed 11 Aug 2025.